Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8612395 | 1.00 | CYP2C19 (0.47) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL26757337 | 0.91 | CYP2C19 (0.50) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL10455028 | 0.87 | CYP2C19 (0.44) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL10808021 | 0.85 | CYP2C19 (0.54) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL599044 | 0.85 | CYP2C19 (0.54) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL3085827 | 0.84 | CYP2C19 (0.41) | CYP2C19HIF1ATAAR1ALDH1A1MAPT | |
| SCHEMBL7041511 | 0.83 | CYP2C19 (0.48) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL11801078 | 0.83 | TAAR1 (0.54) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL28670436 | 0.83 | CYP2C19 (0.44) | CYP2C19HIF1AESR1ESR2TAAR1 | |
| SCHEMBL7041512 | 0.83 | CYP2C19 (0.48) | CYP2C19HIF1AESR1ESR2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003110-B | Aryl beta-aminoketone compound and preparation method thereof | 南京工业大学 | 2022-09-06 | — | — | CN | disclosed |
| EP-3060539-A1 | USE OF ALKANE SULPHONIC ACID FOR PREPARING PHENOLIC ALCOHOL | Arkema France (FR) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015059401-A1 | USE OF ALKANE SULPHONIC ACID FOR PREPARING PHENOLIC ALCOHOL | ARKEMA FRANCE (FR) | 2015-04-30 | — | — | WO | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7615316-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1361622-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-5827855-A | ANTICHOLESTEROL AGENTS TREATING CARDIOVASCULAR DISORDERS; ENZYME INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1998-10-27 | — | — | US | disclosed |
| CN-1039642-C | Derivative of hexahydronaphthalene ester, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-09-02 | — | — | CN | disclosed |
| EP-0605230-B1 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1997-08-27 | — | — | EP | disclosed |
| US-5451688-A | Inhibit biosynthesis of cholesterol | SANKYO COMPANY, LIMITED (JP) | 1995-09-19 | — | — | US | disclosed |
| CN-1094707-A | Hexahydro-naphthalene ester derivative, their preparation and their application aspect treatment | SANKYO CO (JP) | 1994-11-09 | — | — | CN | disclosed |
| EP-0605230-A1 | Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0451714-B1 | Process for the acylation of alkyl aromatics | BASF AG (DE) | 1994-01-05 | — | — | EP | disclosed |
| US-5136089-A | ACYLATION OF ALKYL AROMATIC HYDROCARBONS | BASF AKTIENGESELLSCHAFT (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0451714-A1 | Process for the acylation of alkyl aromatics | BASF Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
| EP-0233450-A2 | Linear salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal-resins of the copolymers, and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP2C19 1411/4885HIF1A 4424/4885ESR1 3804/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP2C19 1391/4885HIF1A 4406/4885ESR1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.